A. Pluzanski

机构：The Maria Sklodowska-Curie National Research Institute of Oncology

发表论文 4 篇 · 总被引 12 次 · h-index 1

代表论文

• OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 (2023 · Journal of Thoracic Oncology · 被引 12)
• MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227 (2024 · Annals of Oncology)
• 41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) (2023 · Journal of Thoracic Oncology)
• EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study (2022 · Journal of Thoracic Oncology)